Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

1.595 +0.075 (+4.93%)
Streaming Delayed Price Updated: 10:55 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Caribou Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
MarketBeat Week in Review – 7/10 - 7/14
As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week 
Via MarketBeat
Topics Economy
News headline image
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces Proposed Public Offering of Common Stock
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
News headline image
Pfizer Just Invested $25 million In This Biotech
Pfizer's investment propels Caribou Biosciences' stock and fuels optimism for its lead candidates: CB-010 and CB-011, both currently in phase 1 trials. 
Via MarketBeat
News headline image
Pfizer (NYSE: PFE) Invests $25 Million in Caribou Biosciences (NASDAQ: CRBU)
On July 6, 2023, Caribou Biosciences, Inc., a significant player in the field of CRISPR genome-editing biopharmaceuticals, announced a $25 
Via Spotlight Growth
News headline image
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences, Inc. (NASDAQ:CRBU) Long Term Investor Alert: Investigation over Possible Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 05/22/2023 -- Certain directors of Caribou Biosciences, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
News headline image
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.